Global Biosimilars Market - Products, Applications and Regulations

• Publication date: November 2012
• Report size: 354 pages

Several of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have the experience of marketing products for the last 5-10 years. On the other hand, several companies’ position is expected to be challenged over the next ten years, since the rapid growth forecast for the biosimilars market has attracted several new companies to enter this lucrative arena. Current leaders, in order to maintain market share, need to...

Several of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have the experience of marketing products for the last 5-10 years. On the other hand, several companies’ position is expected to be challenged over the next ten years, since the rapid growth forecast for the biosimilars market has attracted several new companies to enter this lucrative arena. Current leaders, in order to maintain market share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants.

The global biosimilar market, estimated at US$2 billion in 2012 and expected to touch US$2.7 billion in 2013, is further projected to reach US$19.4 billion by 2018, exhibiting a CAGR of 36.6% over 2009-2018. This growth can be attributed to some of the top-selling biologics coming off-patent over the coming few years and biosimilar manufacturers are bound to make a beeline towards this lucrative opportunity.This report reviews, analyzes and projects the biosimilars market for global and regional markets including the United States, Europe, Asia-Pacific and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and application areas enunciated above. The regional markets further analyzed for 8 more independent countries across Europe – France, Germany, Italy, Spain, the United Kingdom and Rest of Europe; Asia-Pacific – China, India, South Korea and Rest of Asia-Pacific.

The market for application areas of biosimilars analyzed in this study includes Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Others. The report also encompasses the market analysis for product segments – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Others.

This 354 page global market report includes 149 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, application area and product segment.The report covers the brief business profiles of 43 key global players and 54 major players across the United States – 13; Europe – 18; Asia-Pacific – 19 and Rest of World – 4. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of biosimilars. Also enlisting the academic institutions and industry associations engaged in biosimilars, the global list covers the addresses, contact numbers and the website addresses of 168 companies.

Generic Drug Industry in South Korea

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION
1.1 mAbs - All The Rage In Biosimilars’ New Wave
1.2 The Buildup to the Biosimilar Industry
1.3 Current Players: A Sneak Preview
1.3.1 Celltrion
1.3.2 Gedeon Richter
1.3.3 Biocon
1.4 The Big Pharma Industry: Not One to be Left Out
1.4.1 Baxter-Momenta
1.4.2 Merck Serono-Dr. Reddy’s Laboratories
1.4.3 Daiichi Sankyo-Coherus Biosciences
1.4.4 Amgen-Watson
1.4.5 Samsung Biologics-Biogen Idec
1.5 On the Flip Side
1.6 The Winner Takes It All
1.7 Product Outline
1.7.1 What are Biosimilars?
1.7.2 The Process of Approval
1.7.3 Backdrop
1.7.4 The Biologics Price Competition and Innovation Act
1.7.4.1 Data Exclusivity
1.7.5 Biosimilars by Product Type
1.7.5.1 Monoclonal Antibodies
1.7.5.1.1 Production Process
1.7.5.2 Erythropoietin
1.7.5.2.1 Functions of EPO
1.7.5.2.2 Mechanism of Action
1.7.5.2.3 Synthesis and Regulation
1.7.5.2.4 Uses in Medicine
1.7.5.3 Human Growth Hormone
1.7.5.3.1 Recombinant Human Growth Hormone
1.7.5.3.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars
1.7.5.4 Insulin
1.7.5.4.1 Biosimilar Insulin
1.7.5.4.2 The Complexity in Producing Biosimilar Insulin
1.7.5.4.3 Biosimilars and the Regulatory Environment Surrounding Them
1.7.5.4.4 The Market for Insulin Biosimilars
1.7.5.5 Granulocyte Colony-Stimulating Factor
1.7.5.5.1 Biological Function
1.7.5.5.2 Genetics
1.7.5.5.3 Use in Therapeutics
1.7.5.6 Interferons
1.7.5.6.1 Interferon Categorization
1.7.5.6.2 Functions of Interferons
1.7.5.6.3 Interferon Alfa
1.7.5.6.4 Interferon Beta-1a
1.7.5.6.5 Interferon Gamma
1.7.5.7 Other Biosimilars

2. BIOSIMILAR APPLICATIONS – A SNAPSHOT
2.1 Blood Disorders
2.2 Chronic and Autoimmune Diseases
2.3 Growth Hormone Deficiency
2.3.1 Growth Hormone Deficiency in Children
2.4 Oncology
2.4.1 Biosimilars in Oncology and Hematology
2.4.2 Biosimilar G-CSF

3. REGULATORY LANDSCAPE
3.1 The United States Food and Drug Administration
3.2 European Medicines Agency
3.3 Other Developments on the Biosimilar Front
3.3.1 The World Health Organization
3.3.2 Canada
3.3.3 Japan
3.3.4 Latin America
3.3.4.1 Argentina
3.3.4.2 Brazil
3.3.4.3 Mexico
3.3.5 India

4. KEY MARKET TRENDS
Biosimilars Growth to be Driven by Emerging Markets over the Next Decade
Asia Poised to Manufacturing Hub for Biosimilars
Biosimilars: Present Perspectives and Future Implications
Key Considerations for Biosimilars Development and Commercialization in the US
The FDA Guidelines
An Assessment of the Current and Future Trends Of Biosimilars in the United States and India
Biosimilars: Some Quick Facts
The United States Market for Biosimilars
The Indian Market for Biosimilars
Biosimilars could Drive-Down the Cost of Cancer Treatment
FDA Draft Guidance Triggers Evaluation of IP Protection
Biosimilar Therapeutics Showing ‘Similarity’
Key Issues in Biosimilars Commercialization
Biosimilars in the US: Regulation, Strategies, and Impact
Oncologists Urged to Consider Biosimilars as Cost-Effective Treatment Options
Biosimilars Development: Opportunities and Challenges
Key Biosimilar Developments During 2011
Biosimilars Business Blooming in India
Prospects
Indian Initiatives…
Roadblocks Remain
Opportunities for Biosimilars in Emerging Markets

5. KEY GLOBAL PLAYERS
3SBio Inc
Actavis Group HF.
Agilent Technologies, Inc.
Amgen, Inc.
Astrazeneca Plc
Baxter International Inc.
Biocon Ltd.
Biogen IDEC
Bioton S.A.
Boehringer Ingelheim GmbH
Cadila Healthcare Limited
Cangene Corp.
Celltrion, Inc.
Cipla Ltd.
Daiichi Sankyo Company Limited
Dong-A Pharmaceutical Co., Ltd
Dr. Reddy's Laboratories Ltd.
DSM Biologics
GE Healthcare Ltd.
Glaxosmithkline, Plc
Hospira, Inc.
iBio, Inc.
LG Life Sciences
Lonza Group Ltd
Medice Arzneimittel Pütter GmbH & Co KG
Merck & Co., Inc.
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Mylan Inc.
Novartis AG
Perkinelmer, Inc.
Pfizer Inc
Ranbaxy Laboratories Ltd.
Reliance Life Sciences Pvt Ltd
Roche Holding AG
Samsung Biologics Co Ltd
Sandoz International GmbH
Sanofi
Shantha Biotechnics Ltd
Stada Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
Watson Pharmaceuticals, Inc.
Wockhardt Limited

6. KEY BUSINESS TRENDS
ProCognia to expand biosimilar collaboration with UniTargeting Research
Oncobiologics, Boston Oncology to Commercialize Biosimilar Therapies in MENA region
Innovent Biologics Engages Pharmatech Associates for Designing Biosimilars Facility in China
Sandoz Initiates Phase-III Trial for Epoetin Alfa
AET BioTech, BioXpress Therapeutics Sign Deal for Cancer mAb
Reliance Life Sciences Starts Biosimilar Infliximab Trial in India
Fujifilm Kyowa Kirin Biologics to Develop Bevacizumab Biosimilar
Roche’s Rituxan Biosimilar Copies in Market By 2015
Asian Biotech Companies to Pioneer Biosimilars for Renal Failure
Dr Reddy’s Negotiating for Europe Reditux debut
FDA approves Teva Cancer Treatment Biosimilar
FDA Approves Teva’s Tbo-filgrastim Version
iBio and GE Healthcare Announce Global Alliance
Synthon Strikes Deal for Developing Herceptin Biosimilar
Stakeholder Groups Urging FDA to Exempt Plasma Protein Therapy from Biosimilar Pathway
Ranbaxy to Commercialize Three Biosimilars by 2015
Korean FDA Approves Celltrion’s First Monoclonal Antibody
Biocon Announces Positive Results for Biosimilar Insulin Glargine Phase I Trial
Dr Reddy's to Collaborate with Merck Serono on Biosimilars
India Announces New Regulations for Biosimilars
Abbott Challenging Provision in Federal Biosimilar Law
Amgen Endorses EMA Guidance on Biosimilar mAb
Finox Biotech Completes Phase III Trial of Biosimilar r-FSH
Court Rules against Merck in Nasonex Patent Infringement Case
PlantForm’s Biosimilar Trastuzumab Equivalent to Brand Drug In Vivo
Daiichi Sankyo, Coherus BioSciences in Biosimilar Deal
Amgen, PRA in Biosimilars Deal
Pfizer Starts Biosimilar Rituximab Phase I/II trial
Daiichi Sankyo, Coherus Biosciences Collaborating to Commercialize Biosimilars
EMA Reviewing Biosimilar Version of Infliximab
Samsung to Launch Cheaper Biosimilars by 2015
Biocon Commences Advanced Research Centre in Bangalore
Amgen Seeking Clinical Trial Clarification on Biosimilars
Fujifilm, Kyowa in Joint Venture for Humira
Dr Reddy’s Betting High on Biosimilars
GE Healthcare Acquires Xcellerex to Expand Biologicals Offering
Celerion, Ricerca in Biosimilar Alliance
Biocon and Pfizer Conclude Commercialization Agreement
Samsung Biologics and Biogen Idec from Biosimilars Joint Venture
Sandoz Initiates Phase III Trials for Filgrastim and Pegfilgrastim
Hospira begins US Phase III Trial for Biosimilar EPO
Mochida, Fuji Pharma File Biosimilar G-CSF in Japan
Transgene Moves rh-EPO Technology to German TSS Export
Momenta, Baxter in Biosimilar Alliance
Amgen Issued New US Patent on Enbrel
Biocon starts R&D Facility in Bio-XCell, Malaysia
Dong-A to Establish Biosimilar Plant in Songdo
iBio Produces Rituximab in Plants
Pharmerging Countries India and China Promising to Rollout Cheaper Biosimilars
Boehringer Ingelheim Ventures into Biosimilars
Sanofi Announces Fresh Long-Term Objectives
Hospira Looks to Biosimilars and Increased use of Generics for Growth
Stada, Richter to Collaborate on Biosimilar Development
IMS Launches MIDAS Biosimilars
Biosmilars Luring Unlikely Partnerships
Merck, Hanwha Ink Enbrel Deal
Lupin-NeuClone Deal to Develop Oncology Biosimilars
Brazil to Manufacture Biosimilar Adalimumab
Spectrum, Viropro to Develop Rituximab Biosimilar
Sandoz Monitoring Ongoing Biosimilar G-CSF (filgrastim) Study
South Korea to Promote Investments in Biosimilars
Sandoz Announces Start of Phase II Trial for Biosimilar Rituximab
Dr Reddy’s Releases Biosimilar Aranesp

7. GLOBAL MARKET OVERVIEW
7.1 Market Overview by Application Area
7.1.1 Biosimilars Application Area Overview by Global Region
7.1.1.1 Blood Disorders
7.1.1.2 Chronic Diseases
7.1.1.3 Growth Hormone Deficiency
7.1.1.4 Oncology
7.1.1.5 Other Biosimilar Applications
7.2 Market Overview by Product Segment
7.2.1 Biosimilars Product Segment Overview by Global Region
7.2.1.1 Biosimilar Monoclonal Antibodies
7.2.1.2 Biosimilar Erythropoietin
7.2.1.3 Biosimilar Human Growth Hormone
7.2.1.4 Biosimilar Insulin
7.2.1.5 Biosimilar G-CSF
7.2.1.6 Biosimilar Interferons
7.2.1.7 Other Biosimilar Products

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES
1.1 Market Overview by Application Area
1.2 Market Overview by Product Segment
1.3 Major Market Players
Agilent Technologies, Inc.
Amgen, Inc.
Baxter International Inc.
Biogen IDEC
Dynavax Technologies Corporation
Hospira, Inc.
iBio, Inc.
Merck & Co., Inc.
Momenta Pharmaceuticals inc
Mylan Inc.
Perkinelmer, Inc.
Pfizer Inc
Watson Pharmaceuticals, Inc.

2. EUROPE
2.1 Current Market Scenario
2.2 Market Overview by Geographic Region
2.3 Market Overview by Application Area
2.3.1 Biosimilars Application Area Overview by European Region
2.3.1.1 Blood Disorders
2.3.1.2 Chronic Diseases
2.3.1.3 Growth Hormone Deficiency
2.3.1.4 Oncology
2.3.1.5 Other Biosimilar Applications
2.4 Market Overview by Product Segment
2.4.1 Biosimilars Product Segment Overview by European Region
2.4.1.1 Biosimilar Monoclonal Antibodies
2.4.1.2 Biosimilar Erythropoietin
2.4.1.3 Biosimilar Human Growth Hormone
2.4.1.4 Biosimilar Insulin
2.4.1.5 Biosimilar G-CSF
2.4.1.6 Biosimilar Interferons
2.4.1.7 Other Biosimilar Products
2.5 Major Market Players
Actavis Group HF. (Iceland)
Astrazeneca PLC (United Kingdom)
BiogEnerix AG (Germany)
Biopartners GmbH (Switzerland)
Bioton S.A. (Poland)
Boehringer Ingelheim GmbH (Germany)
DSM Biologics (The Netherlands)
GE Healthcare Ltd. (United Kingdom)
Glaxosmithkline, PLC (United Kingdom)
Hexal AG (Germany)
Lonza Group Ltd (Switzerland)
Medice Arzneimittel Pütter GmbH & Co Kg (Germany)
Merck KGaA (Germany)
Novartis AG (Switzerland)
Roche Holding AG (Switzerland)
Sandoz International GmbH (Germany)
Sanofi (France)
Stada Arzneimittel AG (Germany)

2.6 European Market Overview by Country

2.6.1 France
2.6.1.1 Market Overview by Application Area
2.6.1.2 Market Overview by Product Segment

2.6.2 Germany
2.6.2.1 Market Overview by Application Area
2.6.2.2 Market Overview by Product Segment

2.6.3 Italy
2.6.3.1 Market Overview by Application Area
2.6.3.2 Market Overview by Product Segment

2.6.4 Spain
2.6.4.1 Market Overview by Application Area
2.6.4.2 Market Overview by Product Segment

2.6.5 United Kingdom
2.6.5.1 Market Overview by Application Area
2.6.5.2 Market Overview by Product Segment

2.6.6 Rest of Europe
2.6.6.1 Market Overview by Application Area
2.6.6.2 Market Overview by Product Segment

3. ASIA-PACIFIC
3.1 Market Overview by Geographic Region
3.2 Market Overview by Application Area
3.2.1 Biosimilars Application Area Overview by Asia-Pacific Region
3.2.1.1 Blood Disorders
3.2.1.2 Chronic Diseases
3.2.1.3 Growth Hormone Deficiency
3.2.1.4 Oncology
3.2.1.5 Other Biosimilar Applications
3.3 Market Overview by Product Segment
3.3.1 Biosimilars Product Segment Overview by Asia-Pacific Region
3.3.1.1 Biosimilar Monoclonal Antibodies
3.3.1.2 Biosimilar Erythropoietin
3.3.1.3 Biosimilar Human Growth Hormone
3.3.1.4 Biosimilar Insulin
3.3.1.5 Biosimilar G-CSF
3.3.1.6 Biosimilar Interferons
3.3.1.7 Other Biosimilar Products
3.4 Major Market Players
3SBio Inc (China)
Anhui Anke Biotechnology (Group) Co., Ltd. (China)
Bharat Biotech International Limited (India)
Biocon Ltd. (India)
Cadila Healthcare Limited (India)
Celltrion, Inc. (South Korea)
Cipla Ltd. (India)
Claris Lifesciences Limited (India)
Daiichi Sankyo Company Limited (Japan)
Dong-A Pharmaceutical Co., Ltd (South Korea)
Dr. Reddy's Laboratories Ltd. (India)
Intas Biopharmaceuticals Ltd. (India)
LG Life Sciences (South Korea)
Mitsubishi Tanabe Pharma Corporation (Japan)
Ranbaxy Laboratories Ltd. (India)
Reliance Life Sciences Pvt Ltd (India)
Samsung Biologics Co Ltd (South Korea)
Shantha Biotechnics Ltd (India)
Wockhardt Limited (India)

3.5 Asia-Pacific Market Overview by Country

3.5.1 China
3.5.1.1 Current Market Scenario
3.5.1.2 Market Overview by Application Area
3.5.1.3 Market Overview by Product Segment

3.5.2 India
3.5.2.1 Current Market Scenario
3.5.2.2 Market Overview by Application Area
3.5.2.3 Market Overview by Product Segment

3.5.3 South Korea
3.5.3.1 Current Market Scenario
3.5.3.2 Market Overview by Application Area
3.5.3.3 Market Overview by Product Segment

3.5.4 Rest of Asia-Pacific
3.5.4.1 Market Overview by Application Area
3.5.4.2 Market Overview by Product Segment

4. REST OF WORLD
4.1 Market Overview by Application Area
4.2 Market Overview by Product Segment
4.3 Major Market Players
Bioclones (Pty) Ltd. (South Africa)
Cangene Corp. (Canada)
Medicago Inc. (Canada)
Teva Pharmaceutical Industries Ltd. (Israel)

PART C: GUIDE TO THE INDUSTRY
1. NORTH AMERICA
1.1 Canada
1.2 United States

2. EUROPE
2.1 France
2.2 Germany
2.3 Hungary
2.4 Iceland
2.5 Ireland
2.6 Lithuania
2.7 Malta
2.8 Poland
2.9 Russia
2.10 Spain
2.11 Switzerland
2.12 The Netherlands
2.13 United Kingdom

3. ASIA-PACIFIC
3.1 Australia
3.2 China
3.3 India
3.4 Japan
3.5 Singapore
3.6 South Korea
3.7 Taiwan
3.8 Vietnam

4. REST OF WORLD
4.1 Brazil
4.2 Iran
4.3 Israel
4.4 Mexico
4.5 South Africa

PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. THE QUESTIONNAIRE
3. FEEDBACK


Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: The Leading mAbs and Years of Patent Expiry in United States and Europe
Chart 2: The Biosimilar Manufacturers with Most No. of mAbs in Pipeline
Chart 3: The Global Top-5 Biosimilar Manufacturers by Market Shares (%) for 2011 & 2012
Chart 4: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Blood Disorders by Geographic Region
Chart 5: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Chronic Diseases by Geographic Region
Chart 6: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Growth Hormone Deficiencies by Geographic Region
Chart 7: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Oncology by Geographic Region
Chart 8: A Comparative Study on Biosimilars Between The Approaches of The European Union and The United States
Chart 9: The Innovator Products and their Corresponding Biosimilars by Company
Chart 10: Global Biosimilars Market Analysis (2009-2018) in USD Million
Chart 11: Global Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 12: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 13: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 14: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 15: Global Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 16: Glance at 2009, 2013 and 2018 Global Chronic Diseases Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 17: Global Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 18: Glance at 2009, 2013 and 2018 Global Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 19: Global Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 20: Glance at 2009, 2013 and 2018 Global Oncology Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 21: Global Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 22: Glance at 2009, 2013 and 2018 Global Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 23: Global Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 24: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
Chart 25: Global Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 26: Glance at 2009, 2013 and 2018 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 27: Global Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 28: Glance at 2009, 2013 and 2018 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 29: Global Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 30: Glance at 2009, 2013 and 2018 Global Biosimilar Human Growth Hormone Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 31: Global Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 32: Glance at 2009, 2013 and 2018 Global Biosimilar Insulin Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 33: Global Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 34: Glance at 2009, 2013 and 2018 Global Biosimilar G-CSF Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 35: Global Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 36: Glance at 2009, 2013 and 2018 Global Biosimilar Interferons Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 37: Global Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 38: Glance at 2009, 2013 and 2018 Global Other Biosimilar Products Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE
Chart 39: The Projection of Largest Regions in terms of Market Growth (2009-2018) for Biosimilars by Geography – United States, Europe and Asia-Pacific
Chart 40: Global Biosimilars Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million
Chart 41: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

THE UNITED STATES
Chart 42: United States Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 43: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 44: United States Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 45: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

EUROPE
Chart 46: European Biosimilars Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 47: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 48: European Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 49: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 50: European Biosimilars Market Analysis (2009-2018) for Application in Blood Disorders by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 51: Glance at 2009, 2013 and 2018 European Blood Disorders Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 52: European Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 53: Glance at 2009, 2013 and 2018 European Chronic Diseases Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 54: European Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 55: Glance at 2009, 2013 and 2018 European Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 56: European Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 57: Glance at 2009, 2013 and 2018 European Oncology Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 58: European Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 59: Glance at 2009, 2013 and 2018 European Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 60: European Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 61: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other
Chart 62: European Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 63: Glance at 2009, 2013 and 2018 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 64: European Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 65: Glance at 2009, 2013 and 2018 European Biosimilar Erythropoietin Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 66: European Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 67: Glance at 2009, 2013 and 2018 European Biosimilar Human Growth Hormone Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 68: European Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 69: Glance at 2009, 2013 and 2018 European Biosimilar Insulin Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 70: European Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 71: Glance at 2009, 2013 and 2018 European Biosimilar G-CSF Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 72: European Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 73: Glance at 2009, 2013 and 2018 European Biosimilar Interferons Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe
Chart 74: European Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
Chart 75: Glance at 2009, 2013 and 2018 European Other Biosimilar Products Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

France
Chart 76: French Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 77: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 78: French Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 79: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Germany
Chart 80: German Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 81: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 82: German Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 83: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Italy
Chart 84: Italian Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 85: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 86: Italian Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 87: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Spain
Chart 88: Spanish Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 89: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 90: Spanish Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 91: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

United Kingdom
Chart 92: United Kingdom Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 93: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 94: United Kingdom Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 95: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Rest of Europe
Chart 96: Rest of Europe Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 97: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other
Chart 98: Rest of Europe Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million
Chart 99: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

ASIA-PACIFIC
Chart 100: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Geographic Region – China, India, South Korea and Rest of Asia-Pacific in USD Million
Chart 101: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Geographic Region – China, India, South Korea and Rest of Asia-Pacific
Chart 102: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million
Chart 103: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Application Area – Bloo

Generic Drug in South Korea

South Korea Generic Drug Sales, Us$bn

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, Us$bn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, Krwbn

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, Krwbn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, % Of Prescription Sales

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea